

CANCER THERAPEUTIC BASED ON STIMULATION OF NATURAL KILLER T-CELL ANTI-TUMOR ACTIVITY

SUMMARY

Investigators at the National Cancer Institute's Vaccine Branch have found that beta-mannosylceramide (Beta-ManCer) promotes immunity in an IFN-gamma independent mechanism and seek statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize beta-ManCer.

REFERENCE NUMBER

E-034-2010

PRODUCT TYPE

- Therapeutics

KEYWORDS

- immunity
- antibody
- NKT activity

COLLABORATION OPPORTUNITY

This invention is available for licensing.

CONTACT

John D. Hewes
NCI - National Cancer Institute
240-276-5515

John.Hewes@nih.gov

DESCRIPTION OF TECHNOLOGY

Natural killer T cells (NKT) are a unique lymphocyte population that has T-cell and NK cell functional properties in order to rapidly elicit an immune response. alpha-galactosylceramide (alpha-GalCer) is a potent NKT stimulator and induces of IFN-gamma release to promote immunity against tumors and infectious agents. Humans have natural antibodies against alpha-galactose, which may be one of the reasons why the human clinical trials of alpha-GalCer or KRN7000 were not very successful.

Beta-ManCer is a new class of NKT agonist that induces immune responses alone, through nitric oxide and TNF-alpha-dependent mechanisms, or synergistically with alpha-GalCer to enhance alpha-GalCer's efficacy. Since beta-ManCer does not have alpha-galactose, which can be neutralized by natural

antibodies, patients could be treated with multiple doses without negative side effects associated with the loss of IFN-gamma production. Hence, beta-ManCer is a promising anti-cancer treatment either alone or in combinatorial therapies with alpha-GalCer to selectively induce immune responses.

POTENTIAL COMMERCIAL APPLICATIONS

- Cancer therapeutics
- Potent stimulator of NKT activity

COMPETITIVE ADVANTAGES

- Induces tumor immunity through a novel mechanism
- Decreased possibility of neutralization by natural antibodies
- Synergize with alpha-GalCer

INVENTOR(S)

[Masaki Terabe](#) (NCI); Ira Pastan

DEVELOPMENT STAGE

- Discovery (Lead Identification)

PATENT STATUS

- **U.S. Filed:** U.S. Provisional Application No. 61/313,508 filed 3/12/2010

THERAPEUTIC AREA

- Cancer/Neoplasm
- Immune System and Inflammation